Sanofi completes divestiture of Zentiva to Advent
GlobeNewswire

In This Article:

Sanofi completes divestiture of Zentiva to Advent

Paris - October 1, 2018 - Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value).

Sanofi announced the beginning of exclusive negotiations with Advent in April of this year and concluded negotiations June 28. The divestiture is part of Sanofi`s strategy to simplify and reshape the company.


About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life


Media Relations Contact
Jack Cox
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com


Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com

Press release (PDF)


This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
HUG#2218295

Terms and Privacy Policy
Your Privacy Choices
Utah Privacy Notice
More Info

Recommended Stories